Vyalev (Foscarbidopa/Foslevodopa) for Parkinson's Disease

Overview
Vyalev is approved by the U.S. Food and Drug Administration (FDA) for the treatment of motor fluctuations in adults with advanced Parkinson’s disease. This treatment is intended for individuals who experience significant “off” periods (times when medication effects wear off and symptoms return). Vyalev is also known by its drug name, foscarbidopa/foslevodopa.

Vyalev is combination of two drugs, foscarbidopa and foslevodopa. Foscarbidopa inhibits the breakdown of levodopa (which is derived from foslevodopa) before it reaches the brain. Levodopa is converted to dopamine, a critical chemical in the brain that helps regulate movement, which is reduced in people with Parkinson’s disease. Together, these drugs increase dopamine levels, improving motor function.

How do I take it?
Prescribing information states that Vyalev is administered as a continuous subcutaneous infusion, preferably in the abdomen, via the Vyafuser pump. It is prescribed for 24-hour use to provide steady medication levels throughout the day. A health care provider calculates the base dosage, hourly infusion rate, and any optional loading doses or extra doses based on individual needs. Vyalev should be taken exactly as prescribed by a health care provider.

Side effects
According to prescribing information, the most common side effects of Vyalev include infusion site reactions, such as discoloration or swelling, infusion site infections, hallucinations, dyskinesia (involuntary movements), and increased abnormal movements.

Rare but serious side effects may include falling asleep during daily activities, the development of psychosis (a mental state involving hallucinations or delusions), impulse control behaviors (such as compulsive gambling or shopping), and severe infusion site infections. Additionally, discontinuing Vyalev suddenly or reducing the dose too quickly may lead to withdrawal symptoms, including high fever and confusion.

For more information about this treatment, visit:

Vyalev Approval History — Drugs.com

Vyalev (Foscarbidopa and Foslevodopa) Injection, for Subcutaneous Use — U.S. Food and Drug Administration